LITS

#4419
Lite Strategy, Inc. - Common Stock
0.9 8 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.98
0.98
Jahresspanne
0.69
3.23
Tagesänderung
+1.01%
Monatliche Änderung
+1.03%
6 month change
-9.26%
Jahresänderung
-67.11%
Vorheriger Schlusskurs
1.0 0
Open
0.9 8
Tief
0.9 8
Hoch
0.9 8
Volumen
2
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 22 February 2018

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on February 22, 2018. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel changes and related compensation arrangements.

Material Changes

  • Board Expansion: The Board of Directors increased its size by one seat.
  • New Appointment: Mr. Frederick Driscoll was appointed to fill the new vacancy, effective immediately, with a term expiring at the December 2018 annual meeting.
  • Committee Assignment: Mr. Driscoll is expected to serve on the Audit Committee.

Guidance, Outlook, and Management Commentary

Management Commentary: The filing highlights Mr. Driscoll's extensive background, including over 30 years of senior financial management in biotechnology. He previously served as CFO for Flexion Therapeutics, Inc. (2013–2017) and Novavax (2009–2013).

Compensation Arrangements:

  • Mr. Driscoll received an initial stock option grant for 33,333 shares of common stock.
  • 20,000 shares are tied to his appointment and vest over three years.
  • 13,333 shares represent a pro-rated portion of the 2018 annual board grant and vest over four months.
  • The exercise price equals the closing stock price on February 22, 2018.

Risks and Contingencies: The filing explicitly states there are no related party transactions, family relationships, or material plans/contracts involving Mr. Driscoll that require disclosure under Item 404(a) of Regulation S-K.

Investor Verification Checklist

  • Verify the exact closing stock price of MEI Pharma on February 22, 2018, to determine the exercise price of the new options.
  • Confirm the total number of outstanding shares and the dilution impact of the 33,333 new options.
  • Review the attached press release (Exhibit 99.1) for additional strategic context regarding the board expansion.
  • Check subsequent filings to confirm Mr. Driscoll's actual assignment to the Audit Committee.